Open Source Securities: DLL3 is a star target with high expression in SCLC, and various domestic new drugs can be expected in the future.

DLL3 is highly expressed in 80% of SCLC patients, providing a better solution for targeted therapy. Currently, only one product targeting this point has been approved for market, resulting in a favorable competitive landscape.

Zhitong Finance21:50 ET

BEIGENE (06160.HK) issued 0.1032 million shares due to the vesting of restricted stock units.

On December 30th, Gelonghui announced that BEIGENE (06160.HK) will issue 0.1032 million ordinary shares on December 29, 2024, due to the vesting of restricted stock units granted under the equity plan (excluding company directors).

Gelonghui Finance19:05 ET

The Market Doesn't Like What It Sees From BeiGene, Ltd.'s (NASDAQ:BGNE) Revenues Yet

Simply Wall StDec 29 09:08 ET

Seize the innovative leading value and explore the investment opportunities in Hong Kong stocks in the pharmaceutical sector after the deep pullback.

Since the beginning of this year, in the pharmaceuticals Sector, the Hong Kong stock market has demonstrated more cost-effective investment value compared to the A-shares.

Zhitong FinanceDec 28 06:34 ET

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Markets Sluggishly Move to Year-End

MT NewswiresDec 27 08:06 ET

BeiGene Gains FDA Nod for TEVIMBRA, Marking Key Progress in Oncology Treatments

BenzingaDec 27 06:01 ET